FerreiraECarcellerAMAgoguéC. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007;119:52-59.
2.
Moses-KolkoELBogenDPerelJ. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372-2383.
3.
Levinson-CastielRMerlobPLinderNSirotaLKlingerG. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173-176.
4.
SanzEJDe-las-CuevasCKiuruABateAEdwardsR. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482-487.
5.
BotPSemmekrotBAvan der StappenJ. Neonatal effects of exposure to selective serotonin reuptake inhibitors during pregnancy. Arch Dis Child Fetal Neonatal Ed. 2006;91:F153.
6.
OberlanderTFMisriSFitzgeraldCEKostarasXRurakDRiggsW. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004;65:230-237.
7.
WarburtonWHertzmanCOberlanderTF. A register study of the impact of stopping third trimester serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand. 2010;121:471-479.
8.
EyalRYaegerD. Poor neonatal adaptation after in utero exposure to duloxetine. Am J Psychiatry. 2008;165:651.
9.
CabukDSayinADerinözOBiriA. Quetiapine use for the treatment of manic episode during pregnancy. Arch Womens Ment Health. 2007;10:235-236.
10.
HardenCLMeadorKJPennellPB. Management issues for women with epilepsy—focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50:1237-1246.
